Efficacy and safety of valsartan in children aged 1–5 years with hypertension, with or without chronic kidney disease: a randomized, double-blind study followed by open-label phase-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of valsartan in children aged 1–5 years with hypertension, with or without chronic kidney disease: a randomized, double-blind study followed by open-label phase

Published:2021-10-09 Issue:12 Volume:37 Page:2113-2122
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Jankauskiene Augustina¹,Drozdz Dorota²,Wasilewska Anna³,de Paula-Bernardes Rejane⁴,Glazer Robert⁵,Valentin Michele⁵,Tan Monique⁵,Chiang YannTong⁵,Bapatla Kiran⁶

Affiliation:

1. Vilnius University, Vilnius University Hospital “Santaros klinikos”, Vilnius, Lithuania

2. Department of Pediatric Nephrology and Hypertension, Jagiellonian University Medical College, Krakow, Poland

3. Department of Pediatrics and Nephrology, Medical University of Białystok, Waszyngtona, Poland

4. Clínica Nefrokids, Curitiba, Brazil

5. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

6. Novartis Healthcare Pvt Ltd, Hyderabad, India

Funder

Novartis Pharma AG

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2021.1982681

Reference23 articles.

1. What’s new in paediatric hypertension?

2. Long-term safety and tolerability of valsartan in children aged 6 to 17 years with hypertension

3. Clinical assessment of hypertension in children

4. Clinical and Demographic Characteristics of Children With Hypertension

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploration of the Mechanism of Valsartan Treatment in Chronic Renal Failure: Network Pharmacology and Experimental Validation;Journal of Clinical Pharmacy and Therapeutics;2023-10-16

2. Narrative update of clinical trials with antihypertensive drugs in children and adolescents;Frontiers in Cardiovascular Medicine;2022-11-21

3. The Bioequivalence Between Valsartan Oral Solution and Suspension Formulations Developed for Pediatric Use;Clinical Pharmacology in Drug Development;2022-01-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3